Together, these studies provide evidence for multiple roles of cyclophilins and FKBPs in glioblastoma and suggest that drugs that would selectively inhibit their PPIase activity without causing immune suppression might represent attractive candidates for anti-glioma therapy. The gene discussed is FKBP4; the disease is glioblastoma.